ERBB2 and breast carcinoma: For instance, Wahdan-Alaswad and colleagues assessed the efficacy of metformin (5 mM and 10 mM) across glucose conditions (5 mM, 10 mM, and 17 mM) in breast cancer cell lines representing luminal A and B, HER2, and triple-negative subtypes [39].